Author:
Sarszegi Zsolt,Bognar Eszter,Gaszner Balazs,Kónyi Attila,Gallyas Ferenc,Sumegi Balazs,Berente Zoltan
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine
Reference32 articles.
1. Deninger M, Buchdunger E, Duker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653
2. Cohen MH, Williams G, Johnson JR, Duan J et al (2002) Approval summary of imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942
3. Czechowska A, Poplawski T, Drzewoski J, Blasiak J (2005) Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. Chemico-Biol Interact 152:139–150
4. Van Etten RA (2004) Mechanism of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28(suppl 1):S21–S28
5. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand J-B, Force T (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献